先进的组合疗法:这是打破治疗天花板的最佳方法吗?
Panu Wetwittayakhlang1,2, Peter L Lakatos3,4
1Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
先进的组合疗法 (ACT) 通过将两个向治疗相结合,在炎症性肠病 (IBD) 中表现有前途. 最近的一项研究发现,双重生物药物优于性结肠炎的单一药物,这表明ACT可能会克服治疗高原.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前的炎症性肠病 (IBD) 治疗方法通常在有效性方面达到平原.
- 先进的组合疗法 (ACT) 是一种新兴的策略,使用两个向药物来改善结果.
- 现实世界的数据支持对IBD与肠外表现或耐火性疾病的ACT.
研究的目的:
- 审查在炎症性肠病 (IBD) 中先进组合疗法 (ACT) 的证据.
- 评估ACT是否可以克服IBD管理中的治疗上限.
- 讨论ACT在性结肠炎和克罗恩病中的潜力.
主要方法:
- 审查当前的文献和临床试验数据在IBD中ACT.
- 对VEGA研究的分析,这是对性结肠炎 (UC) 双重生物治疗的随机临床试验.
- 关于ACT在耐火性UC和克罗恩病中的证据缺口的讨论.
主要成果:
- 维加研究表明,在性结肠炎 (UC) 中,双生物药与单一药物相比,具有优越的短期疾病控制.
- 累积的现实世界的证据表明,ACT有益于同时患有IBD和肠外表现或耐火性疾病的患者.
- 目前对生物耐药性UC和克罗恩病的ACT存在有限的证据.
结论:
- 先进的组合疗法 (ACT) 显示了增强IBD疾病控制的潜力.
- 需要进一步的研究来确定ACT在特定IBD人群中的作用和最佳使用,包括耐火病例.
- 在管理炎症性肠病方面,ACT可能是克服治疗高原的关键策略.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
07:51High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drug Therapy
Antianxiety Medications
